Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBITDA: 2019-2023

Historic EBITDA for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$36.1 million.

  • ADC Therapeutics' EBITDA fell 1060.85% to -$36.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$127.4 million, marking a year-over-year decrease of 12.77%. This contributed to the annual value of -$123,627 for FY2022, which is 52.76% up from last year.
  • ADC Therapeutics' EBITDA amounted to -$36.1 million in Q3 2023, which was up 8.83% from -$39.6 million recorded in Q2 2023.
  • ADC Therapeutics' 5-year EBITDA high stood at -$10,738 for Q4 2022, and its period low was -$70.7 million during Q1 2021.
  • Over the past 3 years, ADC Therapeutics' median EBITDA value was -$40.4 million (recorded in 2022), while the average stood at -$39.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 166,767.13% in 2020, then spiked by 94.61% in 2022.
  • ADC Therapeutics' EBITDA (Quarterly) stood at -$35,732 in 2019, then tumbled by 159,532.19% to -$52.4 million in 2020, then dropped by 10.23% to -$62,781 in 2021, then spiked by 82.90% to -$10,738 in 2022, then tumbled by 1,060.85% to -$36.1 million in 2023.
  • Its EBITDA stands at -$36.1 million for Q3 2023, versus -$39.6 million for Q2 2023 and -$51.6 million for Q1 2023.